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Abstract: Inflammatory processes in the skin augment collagen degradation due to the up-regulation
of matrix metalloproteinases (MMPs). The aim of the present project was to study the specific
impact of MMP-3 on collagen loss in skin and its interplay with the collagenase MMP-13 under
inflammatory conditions mimicked by the addition of the pro-inflammatory cytokine tumor necrosis
factor-α (TNF-α). Skin explants from MMP-3 knock-out (KO) mice or from transgenic (TG) mice
overexpressing MMP-3 in the skin and their respective wild-type counterparts (WT and WTT)
were incubated ex vivo for eight days. The rate of collagen degradation, measured by released
hydroxyproline, was reduced (p < 0.001) in KO skin explants compared to WT control skin but did
not differ (p = 0.47) between TG and WTT skin. Treatment with the MMP inhibitor GM6001 reduced
hydroxyproline media levels from WT, WTT and TG but not from KO skin explants. TNF-α increased
collagen degradation in the WT group (p = 0.0001) only. More of the active form of MMP-13 was
observed in the three MMP-3 expressing groups (co-incubation with receptor-associated protein
stabilized MMP-13 subforms and enhanced detection in the media). In summary, the innate level
of MMP-3 seems responsible for the accelerated loss of cutaneous collagen under inflammatory
conditions, possibly via MMP-13 in mice.
Keywords: extracellular matrix; inflammation; cytokines; proteinases; interstitial collagens
1. Introduction
More than half a century ago, Gross and Lapière discovered collagenase-1, the first matrix
metalloproteinase (MMP) [1]. Since then, research on MMP has yielded vast information on these
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zinc-dependent endopeptidases [2,3]. Expanding knowledge on MMP function and its impact on
physiological and pathological processes has increased the interest in MMP substrates and has fueled
further research [4]. Stromelysin-1 (MMP-3) belongs to the MMP family and is induced during
development [5], wound repair [6], inflammation [7,8] and cancer [9]. Apart from cleaving extracellular
matrix proteins, e.g., E-cadherin, laminins and type IV collagen, MMP-3 activates cytokines, growth
factors [3,4] and other MMP members, e.g., the collagenases MMP-1, MMP-8 and MMP-13 and
gelatinase B (MMP-9) [3]. In contrast to the collagenases MMP-1, MMP-8 and MMP-13, which
are the main effectors of type I collagen degradation during wound repair, MMP-3 is incapable of
cleaving native type I collagen. MMP-3 has been implicated in many inflammatory diseases, e.g.,
ultraviolet-B irradiation and photoaging [10], arthritis [11], after lung injury [8], vascular disease [12]
and intestinal inflammation [13]. MMP-3-deficient mice show diminished inflammatory responses
to various stimuli [14,15] and reduced cutaneous wound contraction [16]. Pro-inflammatory tumor
necrosis factor-α (TNF-α) is an important mediator of inflammatory processes. TNF-α induces a variety
of MMPs, e.g., MMP-1, MMP-3, MMP-8, MMP-9 and MMP-13 [4]. Apart from TNF-α converting
enzyme (TACE) [17], MMP-3 was shown to activate TNF-α [18,19], yielding a 17 kDa peptide [20].
Activated TNF-α induces the downstream expression and secretion of MMP-3 [21,22]. In our previous
study, human skin explant cultures challenged with TNF-α reacted with a concomitant and increased
MMP-1, MMP-3 and collagen degradation. In this human model, we hypothesized that the increased
collagen degradation was due to the activation of the collagenase MMP-1 by MMP-3 [23].
The primary aim of this project is to study the lack of MMP-3 and the effect of excessive MMP-3 on
collagen degradation in skin. For this purpose, we incubate skin explants from MMP-3 knock-out [24]
and MMP-3 transgenic mice [25]. Under the applied culture conditions, collagen catabolism dominates
and the synthesis of new interstitial collagens is minimal [23]. MMP-1 is not expressed in mice but
MMP-13 is thought to be the main collagenase and functional homologue of human MMP-1 [26].
Therefore, we study the interplay between MMP-3 and MMP-13. To enhance the extracellular detection
of MMP-13, its endocytosis is blocked by adding the receptor-associated protein (RAP). Finally, the
responsiveness of MMP-3-deficient or MMP-3-overexpressing murine skin to an inflammatory stimulus
provided by TNF-α is studied. The broad-spectrum MMP inhibitor GM6001 is included in some
experiments to elucidate the origin of collagen-degrading enzymes.
2. Results
2.1. MMP-3 Expression in the Skin of the Four Murine Genotypes
First, we quantified the MMP-3 mRNA (Figure 1A) and protein (Figure 1B) in the native skin of
the four groups of mice. MMP-3 mRNA and protein were undetectable in the skin of MMP-3-deficient
mice (KO). MMP-3 mRNA (p = 0.016) and protein levels were higher in the skin of transgenic (TG)
animals compared with their wild-type (WTT) controls. WT and WTT contained similar MMP-3
mRNA and protein (approximately 0.2–0.3 ng) levels.
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Figure 1. MMP-3 expression in native mouse skin. (A) MMP-3 mRNA levels determined by qPCR
analysis. Boxes represent the 25th–75th percentile, whiskers the 5th–95th percentile and the horizontal
lines within the boxes indicate the median values. (B) Representative western blot of six independent
experiments of MMP-3 protein expression. Loading was normalized to the total protein (30 µg/lane) of
the tissue extracts. GAPDH indicates the loading/transfer of proteins to the PVDF membrane. The
arrow indicates the latent MMP-3 at 56 kDa. The position of the 50 kDa molecular weight marker is
indicated to the right. KO (BL10), n = 5; WT (BL10), n = 5; WTT (FVB), n = 3; TG (FVB), n = 4.
2.2. Collagen Degradation in Incubated Skin Explants of the Four Murine Genotypes
We measured hydroxyproline in the media as an indicator of cleaved collagen molecules in the
skin. MMP-3-deficient (KO) skin explants (BL10 genetic background) released a total amount of 90 µg
hydroxyproline into the media over the eight-day incubation period, WT (BL10) skin 188 µg, WTT
(FVB) skin 304 µg and MMP-3-overexpressing TG (FVB) skin 285 µg hydroxyproline (Table 1). Notably,
the accumulated hydroxyproline release was higher in FVB WTT (304 µg) versus BL10 WT (188 µg)
mice. Regression analysis was carried out to assess the rate of collagen degradation over the eight-day
culture period and showed significant differences in the total hydroxyproline released between KO
and WT (p < 0.001) skin (Table 1 and Figure 2A) but not between WTT and TG (p = 0.47) skin (Table 1
and Figure 2B).
Table 1. Hydroxyproline (µg) in conditioned media over eight days of culture (mean ± SEM).
Day KO (n = 10) WT (n = 10) WTT (n = 9) TG (n = 10)
0 0 0 0 0
2 3.9 ± 0.2 4.3 ± 0.5 6.8 ± 1.7 5.0 ± 1.0
4 29.9 ± 3.5 49.3 ± 4.7 94.3 ± 12.0 74.4 ± 10.5
6 32.4 ± 3.9 74.9 ± 8.4 79.0 ± 5.7 92.4 ± 11.2
8 24.1 ± 3.6 59.0 ± 5.5 124.4 ± 16.7 113.2 ± 11.8
Accumulated 90.3 187.5 304.5 285.0
Regression analysis
Slope 3.16 9.49 16.9 17.1
p <0.001 0.47
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Figure 2. The effect of the MMP-3 genotype (control), TNF-α treatment and GM6001 treatment on 
collagen degradation in skin measured by the release of hydroxyproline-containing peptides into 
media from KO and WT (A), and WTT and TG (B) skin explants incubated over eight days. The timely 
progression of hydroxyproline release was assessed by regression analysis of the slopes. Mean ± SEM 
(bars). * p < 0.05, ** p < 0.01, *** p < 0.001. The number of animals (n) used for theses analyses is given 
in Table 2. TNF-α (10 ng/mL). GM6001, broad-spectrum MMP inhibitor (10 µM). KO, MMP-3 knock-
out; WT, wild-type control to KO; WTT, wild-type to transgenic mice (TG); TG, MMP-3 
overexpression in skin. Light green bars, day 2; blue bars, day 4; yellow bars, day 6; dark green bars, 
day 8. 
Functional MMP-3 activity was demonstrated by casein zymography in a conditioned medium 
from skin explants of WT mice but not from skin explants of KO mice (Figure 3A). Tissue extracts of 
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skin. Light green bars, day 2; blue bars, day 4; yellow bars, day 6; dark green bars, day 8.
Functional MMP-3 activity was demonstrated by casein zymography in a conditioned medium
from skin explants of WT mice but not from skin explants of KO mice (Figure 3A). Tissue extracts
of incubated skin explants produced the two characteristic and specific 34 and
1
4 type I collagen
fragments by the action of tissue collagenases. TIMP-1 blocked this endogenous collagenolytic activity.
Furthermore, incubation with the organomercurial APMA partly compensated for the lack of MMP-3
(Figure 3B). Consequently, we next wanted to identify the collagenase(s) responsible for the observed
collagenolytic activity.
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inhibitor UK370106 (1 µM) during incubation of the casein containing SDS-PAGE gels abolished the
lysis bands at the arrowheads observed in the control WT media. Open arrowhead, latent MMP-3;
solid arrowhead, active MMP-3. (B) Type I collagenolytic activity of tissue extracts of skin explants
incubated for eight days. Collagenase activity of the extracts was determined in the absence (buffer) or
in the presence of rhTIMP-1 (200 nM) or APMA (1 mM). KO, MMP-3 knock-out; WT, wild-type control
to KO.
2.3. MMP-13 in MMP-3-Deficient and MMP-3-Overexpressing Conditions
Only true tissue collagenases are capable of cleavi g native type I collagen. In rodents, these
are MMP-1a [27], MMP-8 and MMP-13 [26]. MMP-3 indirec ly contribute to collagen lysis via the
activation of collagenases [28]. Here, neither MMP-1a nor MMP-8 was detected by western blot
analysis. The main collagenase responsible for tissue homeostasis in rodents is also claimed to be
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MMP-13 [26]. Therefore, we focused on MMP-13 by determining the mRNA and protein levels in
native and incubated skin.
In native skin, MMP-13 mRNA levels were similar in the KO, WT and WTT groups, while MMP-13
transcripts were undetectable in TG skin (Figure 4A). After eight days of incubation, MMP-13 mRNA
levels differed among the groups with more (p = 0.03) MMP-13 mRNA present in KO skin compared
with WTT skin (Figure 4B).
The MMP-13 protein in conditioned media was analyzed by western blot analysis (Figure 4C).
After four days of culture, bands corresponding to latent (57 kDa) and active (48 kDa) MMP-13
were fainter in KO compared with WT. The catalytic domain of MMP-13, represented by the band at
approximately 29 kDa, was prominent in WT but not in KO. Overall, the expression of MMP-13 was
higher in WT compared to KO. In WTT, only faint bands of latent MMP-13 and of the catalytic domain
fragment at 29 kDa were found. In contrast, TG-conditioned media presented prominent bands at
the positions of latent and active MMP-13. Because MMP-13 detection can be jeopardized by rapid
intracellular uptake via the LRP-1 receptor [29,30], the LRP-1 receptor antagonist RAP was used to
inhibit MMP-13 endocytosis [31]. The presence of RAP during incubation yielded similar MMP-13
bands but fewer intermediate MMP-13 forms and more of the active MMP-13 compared to the controls
(no RAP). After six and eight days of culture, no or minimal amounts of MMP-13 were detected in
conditioned media.Int. J. Mol. Sci. 2019, 20, x FOR PEER REVIEW 5 of 14 
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2.4. Effect of Pro-Inflammatory TNF-α on MMP-3 Tissue Levels, MMP-13 Secretion and Collagen Degradation
We next sought to investigate MMP-3 expression under an inflammatory stimulus provided by
TNF-α. Expectedly, TNF-α addition increased the presence of latent and active MMP-3 in WT skin but
not in KO skin (Figure 5).Int. J. Mol. Sci. 2019, 20, x FOR PEER REVIEW 6 of 14 
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Moreover, TNF-α increased the secretion and activation of latent MMP-13 in the conditioned
media of WT and KO after four days of c lture with more fragments and less latent MMP-13 in WT
and more l tent MMP-13 in KO (Figure 6A). In cont ast to the eff ct of TNF-α on skin from these
animals with BL10 background, only mild effects were observed in the mice with FVB background
(WTT and TG). TNF-α treatment increased the fragmentation of MMP-13 from incubated WTT skin
explants and active MMP-13 at 48 kDa from incubated TG skin explants (Figure 6B).
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Figure 6. Effect of TNF-α on MMP-13 levels in conditioned media of KO and WT (A), and WTT and
TG (B) skin explants incubated without or with 10 ng/mL TNF-α (+TNF) for four days and analyzed
by western blot. The black rrow indicates the position f latent MMP-13 (57 kDa), the white arrow
indicates the active MMP-13 (48 kDa) a d the grey arrow th fragment containing the catalytic domain
(29 kDa). Loading of samples was calculated relative to a pool of day four-conditioned media from all
(n = 17) control samples (50 µl of each sample were mixed). The reference pool was run together with
the samples on 10% SDS-PAGE gels that were stained with Coomassie blue. The density of the common
band at approximately 70 kDa was used for normalization (Supplementary Figure S1). The positions of
protein markers in kDa are indicated to the left. KO (n = 5), MMP-3 knock-out; WT (n = 5), wild-type
control to KO; WTT (n = 3), wild-type to transgenic (TG); TG (n = 4), MMP-3 overexpression in skin.
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The incubation of WT skin explants with TNF-α was translated into increased (p = 0.0001) collagen
degradation compared with the control-treated WT skin explants over the eight-day experimental
period (Figure 2A). In contrast, the TNF-α addition to KO skin explants did not increase (p = 0.06)
collagen degradation further compared with the control. No significant differences in collagen
degradation were found between TNF-α-treated WTT and TG skin explants (Figure 2B).
2.5. Effect of Pro-Inflammatory TNF-α on MMP-2 Secretion in MMP-3-Deficient and -Overexpressing
Conditions
Apart from MMP-3 [32], MMP-2 plays an auxiliary role in activating latent MMP-13 with
the conversion of the intermediate form into the fully activated form of MMP-13 [33]. In the day
eight-conditioned media, no significant differences were found among the four groups with or without
TNF-α addition, although the FVB (WTT and TG) mice tended to secrete less MMP-2 compared with
the BL10 (KO and WT) mice.
3. Discussion
Pro-inflammatory MMP-3 and TNF-α are associated with many diseases that are characterized by
massive tissue destruction and collagen degradation. Previously, we showed that TNF-α promoted
collagenolysis in human skin via the activation of MMP-1, possibly mediated by MMP-3 [23].
Furthermore, earlier studies indicated that MMP-3 increases collagenase activity in cultured murine
bone and cartilage [34,35]. To investigate if MMP-3 per se has a role in collagen catabolism, we
incubated skin from MMP-3-deficient (KO) and MMP-3-overexpressing mice (TG) and their respective
wild-type counterparts (WT and WTT). We found massively reduced collagen degradation and
fragmentation in MMP-3-deficient skin, which could possibly be ascribed to the reduced activation of
the collagenase MMP-13.
The observed effect on collagen degradation could entirely be ascribed to the action of MMP-3
because addition of the non-selective MMP inhibitor GM6001 to the WT skin cultures did not decrease
collagen loss more than that of the KO group. It should be emphasized that our sample size was small
and therefore the risk of making a type II error is apparent.
We isolated proteinases from the incubated murine KO skin that produced the two 14 and
3
4
fragments of native type I collagen triple helix. The extracted proteinases could be activated by
APMA and completely blocked by TIMP-1. This implied that one or more collagenases degraded the
interstitial collagens of the skin and that the lack of collagenase activation appeared to be an underlying
mechanism for reduced collagenolysis in MMP-3 deficiency. Corroborating these data are the findings
by van Meurs et al. [35], who observed the specific single cleavage site in type II collagen in cultured
cartilage from wild-type mice but not from MMP-3-deficient mice.
MMP-13 is thought to be the most powerful collagenase under normal and pathologic
conditions [36]. The two other rodent collagenases, MMP-1a and MMP-8, were not expressed
in significant amounts in our skin explant model. Consequently, we focused on the presence and
activation state of MMP-13. We could show that MMP-3-deficient skin expressed similar amounts of
MMP-13 mRNA compared to controls. The detection of the secreted MMP-13 protein is difficult due to
its high affinity binding to LRP [29,30]. Hence, we added the LRP-1 receptor agonist RAP [31] to block
MMP-13 endocytosis. Despite this manipulation, similar amounts of MMP-13 were present in the
conditioned media of KO and WT samples treated with RAP. Nevertheless, differences in the MMP-13
levels were unlikely the cause for differential collagenolysis seen in MMP-3-deficient conditions. On
the other hand, activated MMP-13 molecular species were reduced in KO skin in comparison with
the wild-type counterpart. Apart from MMP-3, trypsin, plasmin, cathepsin B, MMP-2, MMP-14 and
possibly MMP-8 can activate latent MMP-13 [32,33]. Here, MMP-2 was most likely not involved.
Despite of multiple possibilities for MMP-13 activation, MMP-3 seemed to be the main activator of
MMP-13 in our ex vivo skin model and the absence of the activation function of MMP-3 was not
compensated for by other proteinases.
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Besides being capable of activating proMMP-13, MMP-3 can activate growth factors and cytokines,
notably proIL-1β. IL-1β in turn influences MMP-3 and MMP-13 expression and secretion [37,38].
Having established that collagen loss is severely reduced under MMP-3-deficient conditions and
that the activation, rather than the concentration, of MMP-13 decreases collagen in skin, we next
investigated the effect of pro-inflammatory TNF-α on MMP-13 expression and collagen loss. TNF-α is
known to induce the expression of MMP-3 [23,39], MMP-9 [18,40] and MMP-13 [41]. TNF-α induced
MMP-3 in WT but not in KO skin explants. Moreover, TNF-α augmented the activation of MMP-13
in the WT skin explants, presumably via MMP-3 induction. The increased MMP-13 activation by
TNF-α would explain the increased collagen degradation and fragmentation in WT skin explants not
found in the KO group. One can speculate about the impact of immune cells under in vivo conditions.
Lauridsen et al. [42] reported higher levels of MMP-3 when pericytes were activated with TNF-α and
co-cultured with neutrophils. Our results may well explain the pronounced collagen degradation and
tissue destruction found in highly inflammatory and chronic progressing diseases.
The dependence of collagen degradation on the genetic background of the mice (BL10 versus FVB)
was intriguing. Collagenolysis was not increased in the skin of the FVB mice overexpressing MMP-3.
If we assume that the MMP-13 activity is the rate-limiting factor for collagenolysis in our model, then
the content of MMP-13 is critical. MMP-13 levels were seemingly higher in MMP-3-overexpressed
skin. This may indicate that the activity of MMP-3 was not increased in the MMP-3 transgenic group.
Many proteinases activate proMMP-3 [28], for example, mast cell-derived proteinases [43].
Wild-type skin from BL10 mice responded with a massive increase of collagen degradation, MMP
secretion and activation when TNF-α was added to cultures, whereas FVB murine skin did not respond
to the TNF-α challenge. A similar finding was reported by Martin et al. [44] using a breast cancer
model in C57Bl/6 and FVB/N mice. MMP-mediated effects on tumor angiogenesis were only found
in C57BL/6 mice, with no effect in the FVB/N strain. Therefore, the choice of experimental animals
with the appropriate genetic background is pivotal with respect to the interpretation of results and
translation to the human situation.
4. Materials and Methods
4.1. Animals
MMP-3-deficient mice and the corresponding wild-type mice were donated by Dr. Gary Rosenberg,
University of New Mexico, Health Science Center, Albuquerque, NM, USA [24]. The animals were
crossed back to a homogeneous background of BL10 (C57BL10.RIIIH2r-Mmp3tm1Mol/Ztm) mice for
10 generations. Skin from four-month-old or six-month-old homozygous BL10 MMP-3 knock-out (KO)
and BL10 wild-type (WT) mice was used in this study.
Mice overexpressing MMP-3 under the keratin-5 promoter were first described by Dr. Lisa
McCawley [25]. This overexpression is confined mainly to the keratinocytes of the skin. The sperm of
MMP-3-overexpressing mice was used to inseminate mice of the FVB genotype. The offspring were
mated to mice with a homozygous background. Backcrossing was performed for 10 generations. Skin
from three-month-old FVB MMP-3-overexpressing, transgenic (TG) and FVB wild-type (WTT) mice
were used.
The animals were kept in Makrolon® Type 2L cages at 21 ◦C, with a relative humidity of 55%
± 5% and a light cycle of 10 h/14 h. Sterilized commercial softwood granulate bedding was used
(Lignocel, Altromin, Lage, Germany). Autoclaved commercial pellets (Altromin 1314, Altromin, Lage,
Germany) and autoclaved water were provided ad libitum. The microbiological status was examined as
recommended by FELASA (Federation of European Laboratory Animal Science Associations) and the
absence of listed microorganisms was confirmed [45]. We did not test for the presence of Rodentibacter
sp., Helicobacter spp., Staphylococcus aureus or Klebsiella oxytoca.
The experiments were approved by the local Institutional Animal Care and Research Advisory
Committee (522-27-11/02-00/118, 10 September 2013).
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4.2. Experimental Model and Treatment Groups
After decapitation, the dorsal skin from the male mice of all genotypes was shaved, disinfected
and excised under sterile conditions. The skin samples (approximately 5 cm × 5 cm) were prepared
within 36 h after harvesting. The skin explants were excised with a sterile 8 mm or a sterile 4 mm
trephine and incubated submerged in a serum-free culture medium in 24-well culture plates (Nunc,
Roskilde, Denmark) at 37 ◦C in a humidified atmosphere of 5% CO2/air in a keratinocyte growth
medium (KGM)-2 containing 6 mmol/L glucose, 50 ng/mL amphotericin-B, 100 µg/mL penicillin,
100 U/mL streptomycin and supplemented with 1.4 mM CaCl2 [23].
For each animal genotype, i.e., KO, WT, WTT or TG (Table 2), 8 mm skin explants were incubated
in 1.0 mL medium in the absence (control) or presence of rmTNF-α (Sigma-Aldrich, St. Louis, MO, USA)
or the broad-spectrum hydroxamate MMP inhibitor GM6001 (Merck-Millipore, Molsheim, France).
Table 2. Experimental groups.
Group Control TNF-α 1 GM6001 2
KO n = 10 n = 10 n = 5
WT n = 10 n = 10 n = 5
WTT n = 9 n = 9 n = 4
TG n = 10 n = 10 n = 5
1 10 ng/mL. 2 10 µM.
Because MMP-13 is rapidly endocytosed intracellularly, extracellular detection of MMP-13 can
be difficult. The internalization of MMP-13 is mediated by LRP-1 [29,30]. RAP is a ligand-binding
antagonist for LRP-1 and inhibits proteinase endocytosis [31]. Hence, we used RAP in a second series
of experiments to facilitate extracellular MMP-13 detection by blocking rapid internalization. Skin
explants (4 mm) were incubated in 0.25 mL medium in the absence (control) or presence of the indicated
treatments in Table 3.
Table 3. Experimental setting for the RAP (receptor-associated protein) experiment.
Group Control TNF-α
1 GM6001 2
0 +RAP 3 0 +RAP 3 0 +RAP 3
KO n = 4 n = 4 n = 4 n = 4 n = 4 n = 4
WT n = 4 n = 4 n = 4 n = 4 n = 4 n = 4
WTT n = 4 n = 4 n = 4 n = 4 n = 4 n = 4
TG n = 4 n = 4 n = 4 n = 4 n = 4 n = 4
1 10 ng/mL. 2 10 µM. 3 250 nM.
Conditioned media were harvested and replaced by a fresh medium every second day. After
eight days of incubation, the experiments were terminated, media were harvested, and skin explants
were kept at −80 ◦C until analysis for MMP-3 and MMP-13 mRNA, and MMP-3 protein. Conditioned
media were stored at −20 ◦C until analysis for hydroxyproline and MMP-13 protein.
4.3. Analyses
4.3.1. Hydroxyproline Assay
Hydroxyproline levels in the conditioned media from days two, four, six and eight were measured
colorimetrically [23].
4.3.2. MMP-3 and MMP-13 mRNA Determined by qPCR
RNA was isolated from skin explants (approximately 30 mg) using TRIzol reagent (Thermo Fisher
Scientific, Schwerte, Germany). Total RNA (approximately 100 ng) were reverse-transcribed into cDNA
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and subsequently analyzed for 40 cycles in qPCR. The qPCR was conducted on a 7500 Fast Real Time
PCR system (Thermo Fisher Scientific, Schwerte, Germany) with TaqMan probes for murine MMP-3
(Mm00440295_m1) and murine MMP-13 (Mm00439491_m1). Murine β-actin (Mm02619580_g1) and
murine peptidylprolyl isomerase A (Mm02342430_g1) were used as housekeeping genes. Each reaction
was run in triplicate and the relative quantity of MMP-3 or MMP-13 was determined using the ∆∆CT
method [46].
4.3.3. Casein and Gelatin Zymography
Casein zymography (β-casein, Sigma-Aldrich, St. Louis, MO, USA) was performed as described
elsewhere [23]. Mark12™ unstained protein standard (LC5677, Thermo Fisher Scientific, Schwerte,
Germany) was run in a parallel lane. After electrophoresis, the gels were incubated in 50 mM Tris-HCl
(pH 7.5) containing 10 mM CaCl2, 1 µM ZnCl2 and 0.1% Triton X-100 with or without the selective
MMP-3 inhibitor UK370106 (R&D Systems, Minneapolis, MN, USA) for 72 h at 37 ◦C.
Gelatin zymography was used to analyze the MMP-2 content in 4× concentrated (Amicon
Ultra-0.5 filter, Merck-Millipore, Darmstadt, Germany) conditioned media [23]. rmMMP-2 (924-MP,
R&D Systems, Minneapolis, MN, USA) was run at 2 ng in parallel to estimate the MMP-2 content of
the samples by the image analysis of digitized gels [47].
4.3.4. Collagenase Activity
Tissue extracts of skin explants that had been incubated for eight days were prepared together
with 1 mM Pefabloc SC (Roche Diagnostics GmbH, Mannheim, Germany) and concentrated 4x by
Amicon Ultra-0.5 [23]. The collagenolytic activity was determined by incubating the extracts with
native (trypsin-resistant) type I collagen from bovine skin for 240 h at 22 ◦C, as described elsewhere [23].
rhTIMP-1 (R&D Systems, Minneapolis, MN, USA) was added to one set of reaction vials to a final
concentration of 200 nM and APMA (Sigma-Aldrich, St. Louis, MO, USA) to another set of reaction
vials to a final concentration of 1 mM. TIMP-1 or APMA were present during the entire 240 h
incubation period.
4.3.5. Western Blot Analyses
Native and incubated skin explants were homogenized (Ultra-Turrax® T25 Basic, IKA Werke
GmbH, Staufen, Germany) in RIPA (radioimmunoprecipitation assay) buffer or modified RIPA buffer
at pH 7.4 (5 µL/mg tissue) containing 0.1 M Tris-HCl, 0.15 M NaCl, 1% Triton X-100, 0.1% SDS (sodium
dodecyl sulfate) [48] and EDTA (ethylendiamintetraacetate)-free proteinase inhibitor cocktail and
1 µM pepstatin A. Homogenates were then centrifuged at 12,000× g for 10 min, and the supernatants
were stored at −20 ◦C until analysis. Protein concentration was determined using the Pierce BCA
(bicinchoninic acid) Protein Assay kit (Thermo Fisher Scientific, Schwerte, Germany).
Tissue extracts, conditioned media, molecular weight markers (RPN800E, Sigma-Aldrich,
St. Louis, MO, USA) and rmMMP-3 (RPA101Mu01, Cloud-Clone Corporation, Katy, TX, USA)
were electrophoresed on 10% SDS-PAGE gel under reducing conditions and electrotransferred for
seven min using iBlot apparatus (Invitrogen, Carlsbad, CA, USA) onto a polyvinylidene fluoride
(PVDF) membrane (Immobilon®, Merck-Millipore, Darmstadt, Germany). Membranes were blocked
in 5% fat-free milk (Bio-Rad Laboratories, Hercules, CA, USA) for 1 h at room temperature and
incubated with primary antibodies for 18 h at 4 ◦C (rabbit polyclonal anti-mouse MMP-1a antibody
(1:200 dilution; 250750, Abbiotec, San Diego, CA, USA), anti-mouse MMP-3 peptide antibody [49,50],
rabbit polyclonal anti-MMP-8 (1:1000 dilution; ABT38, Merck-Millipore, Darmstadt, Germany), rabbit
polyclonal anti-MMP-13 antibody (1:250 dilution; ab39012, Abcam, Cambridge, UK), mouse monoclonal
anti-β-actin antibody (1:40,000 dilution; A5441, Sigma-Aldrich, St. Louis, MO, USA), rabbit polyclonal
anti-β-actin antibody (1:1000 dilution; #4967, Cell Signaling Technology, Leiden, The Netherlands) or
rabbit monoclonal anti-GAPDH antibody (1:1000 dilution; #2118, Cell Signaling Technology, Leiden,
The Netherlands)). Then, membranes were incubated for 1 h at room temperature with IgG-horseradish
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peroxidase secondary antibodies (Jackson ImmunoResearch, Ely, UK), and a specifically bound antibody
was detected using an immunodetection kit (Amersham ECL Prime Western Blotting Detection Reagent,
GE Healthcare Life Sciences, Amersham, UK), and then exposed to X-ray film (Amersham Hyperfilm
ECL, GE Healthcare Life Sciences, Amersham, UK).
For the analysis of MMP-13 in conditioned media by western blot, the loading of samples was
normalized from Coomassie blue-stained 10% SDS-PAGE gels because the BCA assay was not sensitive
enough for these samples. On each gel, the samples were run with a reference sample composed of
conditioned media from all control-treated samples (50 µL of each sample were mixed) in each specific
experiment. The density of a common band at approximately 70 kDa was determined by ImageJ™ and
used for the normalization of protein loading (Supplementary Figure S1).
4.4. Statistics
The Shapiro–Wilk test was used to assess for normality. A Student’s t-test was used for the
statistical analysis of results with normal distribution, and otherwise the Wilcoxon Rank Sum test and
the Mann–Whitney U test using GraphPad Prism 8.0.2 software (GraphPad Software Inc., San Diego,
CA, USA) were applied. For the comparison of hydroxyproline release over time, the slopes for two
independent samples were compared after regression analysis. The Bonferroni correction was used in
the cases of multiple comparisons. p < 0.05 was considered significant.
5. Conclusions
Collagen degradation in murine skin is MMP-3 and MMP-13 dependent, with MMP-3 being
a potent activator of MMP-13. The pro-inflammatory cytokine TNF-α enhanced collagenolysis
via the up-regulation of MMP-3 and increased the activation of MMP-13. Co-targeting MMP-3 in
inflammatory diseases seems an appropriate measure to enhance the anti-inflammatory impact of
clinically used drugs.
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5234/s1.
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APMA Aminophenylmercuric acetate
GAPDH Glyceraldehyde-3-phosphate dehydrogenase
IL-1β Interleukin-1β
LRP Lipoprotein receptor-related protein
MMP Matrix metalloproteinase
PVDF Polyvinylidene fluoride
RAP Receptor-associated protein
TIMP Tissue inhibitor of metalloproteinases
TNF-α Tumor necrosis factor-α
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